CureVac and Rentschler Biopharma Ramp up for Joint Manufacturing of COVID-19 Vaccine, CVnCoV CureVac further strengthens its global manufacturing network Rentschler Biopharma responsible for manufacturing,

CureVac and Rentschler Biopharma

Ramp up for Joint Manufacturing of COVID-19 Vaccine, CVnCoV

Germany and Boston/Milford, MA, USA, February 1, 2021 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company

developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Rentschler Biopharma SE, a leading

global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the companies have

initiated the set-up of manufacturing capabilities for CureVac s COVID-19 vaccine, CVnCoV.

Rentschler Biopharma is gearing up for

largescale cGMP (Current Good Manufacturing Practice) production of the formulated mRNA for CVnCoV. CureVac has started the clinical

Phase 2b/3 trial with its mRNA-based vaccine candidate against SARS-CoV-2, and therefore, is preparing the start of commercial

production to meet global demands. Rentschler Biopharma contributes to the manufacturing of active pharmaceutical ingredient, downstream

processing and formulation of drug substance for the vaccine.

The companies entered into a collaboration

in November 2020 with the set-up of dedicated production lines at the Rentschler Biopharma site in Laupheim, Germany. Currently,

optimization of the production process is taking place to increase mRNA yield. It is expected to produce more than 100 million

doses of the CureVac vaccine per year in Laupheim.

Dr. Florian von der M lbe, Chief Production

Officer of CureVac, said: "We are pleased to partner with Rentschler Biopharma, whose quality work is well known in the industry,

to conduct key aspects of the CVnCoV production process. CureVac has started building an integrated European vaccine manufacturing

network with several CDMO partners. With this strategy, the company will expect a significant increase in manufacturing capacity

for CVnCoV, potentially reaching up to several hundred million doses per year while mitigating potential supply chain risks."

Dr. Frank Mathias, CEO of Rentschler Biopharma,

said: "Rentschler Biopharma has extensive experience in working with the most complex biopharmaceuticals and our expert team

is dedicated to meeting CureVac's high expectations in producing their mRNA vaccine against COVID-19. We are preparing now

to be ready to manufacture commercial supply, and are already setting up the production suite. We are currently looking to hire

up to 80 highly qualified new team members, such as lab technicians and bioprocess engineers, to contribute to this important project

and help us satisfy the increasing demand for life-saving biopharmaceuticals in the long-term."

Federico Pollano, Senior Vice President

Global Business Development of Rentschler Biopharma, added: "From the beginning of our planning process, the relationship

between the CureVac and Rentschler Biopharma teams has been highly collaborative, driven by our common goal of doing our part to

address the major global need for safe and effective vaccines against COVID-19. We are working tirelessly to optimize the production

chain and then obtain the necessary regulatory certifications, so that we can begin manufacturing large-scale commercial supply

as soon as possible."

CureVac began development of its mRNA-based

COVID-19 vaccine candidate in January 2020. The vaccine is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized

full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nano Particles (LNPs). Phase 1 and 2a clinical trials

of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was

generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell

activation. The quality of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response

after natural COVID-19 infection. The data supported CureVac's decision to advance a 12 g dose into its current pivotal

Phase 2b/3 study, the HERALD study, which started in December 2020. Clinical trial material is provided by the company's

substantial production capacities for mRNA vaccines at its headquarters in T bingen, supported by the current expansion of

manufacturing capacities in Europe, allowing broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.

CureVac is a global biopharmaceutical company

in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile

biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified

mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based

on its proprietary technology, the company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer

therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq

in August 2020. It is headquartered in T bingen, Germany, and employs more than 500 people at its sites in T bingen,

Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

About Rentschler Biopharma SE

Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From

its headquarters in Laupheim, Germany and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing

of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler

Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level

quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality

and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the

biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned

company with about 1,000 employees. For further information, please visit www.rentschler-biopharma.com.

Follow Rentschler Biopharma on LinkedIn and Facebook.

Forward-Looking Statements

This press release contains statements

that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation

Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections

of CureVac (the "company") regarding future events or future results, in contrast with statements that reflect historical

facts. Examples include discussion of the potency efficacy of the company's vaccine candidate and the company's strategies,

financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology

such as "anticipate," "intend," "believe," "estimate," "plan," "seek,"

"project," or "expect," "may," "will," "would," "could,"

"potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking

statements are based on management's current beliefs and assumptions and on information currently available to the company.

However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue

reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances,

including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability

to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty

of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture

any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing

competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business

and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability

to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such

risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such

statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially

from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof.

The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce

the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference

the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents

by visiting EDGAR on the SEC website at www.sec.gov.